重症监护常用100种药品说明书中种族与民族术语的系统分析
本研究系统审查了重症监护中常用100种药品的生产厂家说明书,评估其中明确涉及种族或民族术语的使用频率、按药物类别分布及在说明书章节中的位置。结果显示,21份说明书共出现94次种族相关术语,「Black」出现频率最高(占29.8%)。部分术语未被联邦政府报告推荐使用,可能影响临床决策与用药评价。
要点
- 100种ICU常用药中仅21份说明书含种族/民族术语,共94次。
- 「Black」是最常出现的种族术语,占94次中的29.8%(28/94)。
- 种族术语最多见于「Adverse Reactions」章节,占31.9%(30/94)。
核心结论
- 部分说明书中的种族/民族术语未被联邦政府报告列出或明确不推荐使用,可能影响临床决策与用药评价。
研究设计与样本
- 通过审查各药品生产厂家说明书,对100种重症监护常用药的种族/民族术语进行编码和量化分析。
主要发现
- 100份说明书中有21份出现种族/民族相关术语,累计94次。
- 「Black」出现频率最高,占94次中的29.8%(28/94)。
- 按药物类别,种族术语使用频率从高到低依次为:糖尿病药物、抗凝药、抗菌药、抗高血压药、降胆固醇/降脂药。
- 按说明书章节,约三分之一(31.9%,30/94)的术语出现在「Adverse Reactions」章节。
临床怎么用
- 临床药师阅读说明书时应关注种族/民族术语的表述及其所在章节,结合患者背景评估其临床相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the use of terms denoting race/ethnicity in product labeling for 100 of the medications most commonly used in critically ill patients and to assess this information for overall frequency, frequency by drug class, and frequency within package insert sections to highlight the need for standardized and consistent use of Food and Drug Administration-approved terminology in drug packaging and other informational materials. METHODS: Data were collected by reviewing individual drug manufacturer package inserts. Each package insert was assessed for terminology that explicitly referenced race or ethnicity, and these terms were coded and quantified. After evaluating each of the 100 package inserts, a spreadsheet detailing the usage and presence of race and ethnicity terminology, including its location within the insert and frequency was created. This composite list was then analyzed to identify patterns in using such terminology. RESULTS: A cumulative analysis of all race/ethnicity-based terminology found in the package inserts for the top 100 intensive care unit drugs demonstrated that race/ethnicity-related terminology occurred 94 times in 21 package inserts. Summarizing these categories by number of occurrences showed that the race/ethnicity-based term "Black" occurred most frequently (in 29.8% [28/94] of package inserts]). Concerning the frequency of race/ethnicity-related terminology by agent class, the most frequent use of these terms was (in descending order): diabetes medications, anticoagulation, antimicrobials, antihypertensives, and medications used for cholesterol/lipid lowering. Regarding the frequency of the terms in the main sections of a package insert, most of these terms (a third of the total occurrences) were in the "Adverse Reactions" section (in 31.9% [30/94] of package inserts]). CONCLUSION: Some of the terminology found in the package inserts in our study was either not listed or specifically not recommended for use in federal government reporting. These findings elucidate the prevalence and contexts in which race/ethnicity-related terminology is employed, highlighting its potential impact on clinical decision-making and drug use evaluation.
引用
- Erstad BL, Agundez J, Nishikawa N, et al. A systematic analysis of package insert information referencing race and ethnicity for 100 medications commonly used in critically ill patients. Am J Health Syst Pharm. 2025. PMID: 40202460. doi:10.1093/ajhp/zxaf087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。